Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01818180
Other study ID # 2009/19
Secondary ID
Status Terminated
Phase N/A
First received March 19, 2013
Last updated March 21, 2013
Start date May 2010

Study information

Verified date March 2013
Source Hopital Foch
Contact n/a
Is FDA regulated No
Health authority France : Agence Française de Sécurité Sanitaire des Produits de Santé
Study type Interventional

Clinical Trial Summary

Evaluation of the effect of URELL consumption on the occurrence of recurrent urinary tract infection (Acute cystitis, pyelonephritis and asymptomatic bacteriuria).


Recruitment information / eligibility

Status Terminated
Enrollment 11
Est. completion date
Est. primary completion date September 2012
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria:

- Pregnant woman in her 4th gestational month or more, having urinary tract infection.

Exclusion Criteria:

- Pregnant woman with organic or functional urinary tract malformations

- Diabetic patients

- HIV positive

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double Blind (Subject, Investigator)


Intervention

Dietary Supplement:
URELL

Other:
Placebo


Locations

Country Name City State
France Hôpital FOCH Suresnes

Sponsors (1)

Lead Sponsor Collaborator
Hopital Foch

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Recurrence of Urinary tract infections From the 4th gestational month till the end of pregnancy (about the 40th gestational week) No
See also
  Status Clinical Trial Phase
Recruiting NCT04095572 - Alternative Prophylaxis in Female Recurrent Urinary Tract Infections Phase 4
Active, not recruiting NCT03697096 - The INSPIRE-ASP UTI Trial N/A
Recruiting NCT02829060 - Endourology Disease Group Excellence (EDGE) Consortium: Antibiotics (Abx) for Percutaneous Nephrolithotomy (PCNL) Part 2 N/A
Completed NCT02728089 - Study of Ceftolozane/Tazobactam (MK-7625A) in Japanese Participants With Uncomplicated Pyelonephritis and Complicated Urinary Tract Infection (MK-7625A-014) Phase 3